Andrew Hill - Researcher for Sale - Ivermectin related

quote:

---

On Jan. 6 of 2021, Hill testified enthusiastically before the NIH COVID-19 Treatment Guidlelines Panel in support of ivermectin’s use. Within a month, however, Hill found himself in what he describes as a “tricky situation.” Under pressure from his funding sponsors, Hill then published an unfavorable study. Ironically, he used the same sources as in the original study. Only the conclusions had changed. Shortly before he published, Dr. Tess Lawrie, Director of the Evidence-based Medicine Consultancy in Bath, England, and one of the world’s leading medical research analysts, contacted Hill via Zoom and recorded the call (transcript below). Lawrie had learned of his new position and reached out to try to rectify the situation.

---

quote:

---

Lawrie then asks again: Would you tell me? I would like to know who pays you as a consultant through WHO?

Hill: It’s Unitaid.

Lawrie: All right. So who helped to … Whose conclusions are those on the review that you’ve done? Who is not listed as an author? Who’s actually contributed?

Hill: Well, I mean, I don’t really want to get into, I mean, it … Unitaid …

Lawrie: I think that . . . it needs to be clear. I would like to know who, who are these other voices that are in your paper that are not acknowledged? Does Unitaid have a say? Do they influence what you write?

Hill: Unitaid has a say in the conclusions of the paper. Yeah.

Lawrie: Okay. So, who is it in Unitaid, then? Who is giving you opinions on your evidence?

Hill: Well, it’s just the people there. I don’t …

Lawrie: So they have a say in your conclusions.

Hill: Yeah.

Lawrie: Could you please give me a name of someone in Unitaid I could speak to, so that I can share my evidence and hope to try and persuade them to understand it?

Hill: Oh, I’ll have a think about who to, to offer you with a name … but I mean, this is very difficult because I’m, you know, I’ve, I’ve got this role where I’m supposed to produce this paper and we’re in a very difficult, delicate balance …

Lawrie: Who are these people? Who are these people saying this?

Hill: Yeah … it’s a very strong lobby …

Lawrie: Okay. Look, I think I can see kind of a dead end, because you seem to have a whole lot of excuses, but, um, you know, that to, to justify bad research practice. So I’m really, really sorry about this, Andy.

I really, really wish, and you’ve explained quite clearly to me, in both what you’ve been saying and in your body language that you’re not entirely comfortable with your conclusions, and that you’re in a tricky position because of whatever influence people are having on you, and including the people who have paid you and who have basically written that conclusion for you.

Hill: You’ve just got to understand I’m in a difficult position. I’m trying to steer a middle ground and it’s extremely hard.

Lawrie: Yeah. Middle ground. The middle ground is not a middle ground … You’ve taken a position right to the other extreme calling for further trials that are going to kill people. So this will come out, and you will be culpable

---

quote:

---

Lawrie was unable to persuade Hill, who instead of joining her team as lead author, went ahead and published his manipulated findings. Four days before publication, Hill’s sponsor Unitaid gave the University of Liverpool, Hill’s employer $40 million. Unitaid, it turns out, was also an author of the conclusions of Hill’s study.

---